Gamma Medica announced that New York’s first clinical LumaGEM Molecular Breast Imaging (MBI) system has been installed at Mercy Center, a member of Catholic Health Services of Long Island.
MBI is a secondary screening and diagnostic tool used for women who have dense breast tissue and those at risk of being diagnosed with cancer.
“We are thrilled to partner with the Mercy Medical Center to provide the women of New York access to state-of-the-art MBI technology,” said Philip Croxford, Gamma Medica president and CEO in a statement.
“This is just the latest milestone in Mercy’s longstanding dedication to the fight against cancer,” said Mercy’s Executive Vice President and Chief Administration Officer Ron Steimel.
According to a study published in the American Journal of Roentgenology, MBI increases early detection in women who are at high risk of being diagnosed with cancer, due to dense breast tissue. In the retrospective clinical study published, MBI was able to detect 7.7 cancers per 1,000 women screened that were not found using mammography.